(0)

ViroCyt

ViroCyt is the leader in the field of rapid virus quantification. Our goal is to provide the tools that deliver meaningful improvements to mission critical processes, such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role.

Sign up for the Going Viral eNewsletter and stay up-to-date on the latest developments in rapid virus quantification.

Recent News

up
down
  • July 2016 Edition of the “Going Viral” Newsletter Now Available

    Click here to access the current issue.

    Read More arrow
  • ViroCyt® Acquired by Sartorius

    Broomfield, Colorado, USA – ViroCyt®, a leader in rapid virus quantification, announced today that it has been acquired by Sartorius, a leading international pharmaceutical and laboratory tools provider. The approximate valuation of the transaction is $16M. The importance of viruses as both a health threat and as a tool for addressing a growing list of diseases continues to  Continue Reading »

    Read More arrow
  • ViroCyt® Continues to Innovate for the Gene Therapy Field

    BROOMFIELD, CO–(Marketwired – May 4, 2016) – ViroCyt®, the leader in rapid virus quantification, announced today the release of new member of the ViroTag® portfolio of antibody-based detection reagents: ViroTag AAV5. Adeno-Associated Virus, or AAV, is a family of 12 different serotypes, and are a major tool in the gene therapy field, with well over 100  Continue Reading »

    Read More arrow
  • ViroCyt® Announces a Paradigm Shift in Influenza Virus Quantification: ViroTag® INVX

    BROOMFIELD, CO–(Marketwired – March 24, 2016) – ViroCyt®, the leader in rapid virus quantification, announced today that it has developed and launched an antibody-based detection system for influenza capable of determining virus titer for both flu A and flu B during a one minute analysis. Every year, the flu virus causes millions of cases of illness  Continue Reading »

    Read More arrow
  • ViroCyt Releases ViroTag AAV2-3: Rapid and Direct Quantification of Gene Therapy Viral Vectors

    BOULDER, CO–(Marketwire – January 19, 2016) – ViroCyt, the leader in rapid virus quantification, announced today the release of the most recent addition to its ViroTag portfolio: ViroTag AAV2-3.  When combined with the Virus Counter 3100, this reagent enables real-time quantification of Adeno-associated virus serotypes 2 and 3, both of which are currently being developed as  Continue Reading »

    Read More arrow

Upcoming Events


Aug
15

Bioprocessing Summit (Boston, Massachusetts) Event Details

Oct
4

BioProcess International Conference & Exposition (Boston, Massachusetts) Event Details

Oct
10

World Vaccine Congress (Barcelona, Spain) Event Details